Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05425940 · ClinicalTrials.gov registry record · Phase 3
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
A Phase 3 study of Colorectal Cancer, sponsored by Exelixis.
- Active
- Registry status
- Phase 3
- Development phase
- 901
- Enrollment target
- 20
- Study locations
NCT05425940: Active Phase 3 study of Colorectal Cancer, sponsored by Exelixis.
NCT05425940 is a Phase 3 study of Colorectal Cancer that is active but no longer recruiting, run by Exelixis. The registered enrollment target is 901 participants, below the 1,542-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (42% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05425940, a Phase 3 study of Colorectal Cancer, is active but no longer recruiting, sponsored by Exelixis.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 901 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to evaluate XL092 + atezolizumab versus regorafenib in participants with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or are intolerant to standard-of-care (SOC) therapy.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG Regorafenib
- DRUG XL092
Study Locations (20)
California
- Exelixis Clinical Site #9 - Duarte
- Exelixis Clinical Site #55 - La Jolla
- Exelixis Clinical Site #77 - Los Angeles
- Exelixis Clinical Site #105 - Orange
- Exelixis Clinical Site #80 - Santa Monica
- Exelixis Clinical Site #5 - Santa Rosa
- Exelixis Clinical Site #82 - Sylmar
- Exelixis Clinical Site #58 - Torrance
- Exelixis Clinical Site #81 - Whittier
Arizona
- Exelixis Clinical Site #30 - Phoenix
- Exelixis Clinical Site #70 - Tucson
Florida
- Exelixis Clinical Site #16 - Miami Beach
- Exelixis Clinical Site #60 - Orlando
Alabama
- Exelixis Clinical Site #65 - Jonesboro
Connecticut
- Exelixis Clinical Site #125 - New Haven
Georgia
- Exelixis Clinical Site #4 - Marietta
Illinois
- Exelixis Clinical Site #3 - Joliet
Indiana
- Exelixis Clinical Site #102 - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 901 participants |
| Start Date | 2022-09-07 |
| Est. Completion | 2027-01 |
| Phase | Phase 3 |
What the registry record for NCT05425940 still lists
NCT05425940 is an interventional study that assigns participants to a tested intervention. The registered 901 participants enrollment target is mid-sized for trials with a published cap, below the 1,542-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (42% lower).
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Atezolizumab is the first listed.
NCT05425940 names 20 study sites across 10 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT05425940 about?
NCT05425940 is a clinical study titled "Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer". The primary purpose of this study is to evaluate XL092 + atezolizumab versus regorafenib in participants with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or are intolerant to standard-of-care (SOC) therapy.
What is the current status of trial NCT05425940?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 901 participants. The study started on 2022-09-07. Estimated completion is 2027-01.
What conditions does trial NCT05425940 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT05425940?
The interventions under investigation include: Atezolizumab (DRUG), Regorafenib (DRUG), XL092 (DRUG).
Who is sponsoring clinical trial NCT05425940?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05425940 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05425940's enrollment target sits among peer trials
901 52nd of 381 higher than 330 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
RECRUITING · Phase 3
-
The Northern-European Initiative on Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery
COMPLETED · Phase 3
-
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
COMPLETED · Phase 3
-
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
COMPLETED · Phase 3
-
Laparoscopic-Assisted Surgery Compared With Open Surgery in Treating Patients With Colon Cancer
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05769777 · 901 participants · Phase 2
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI